RE:Trust the numbers...Thats's probably because of the receivables. When you sell, you get paid later, let's say 30 to 90 days. They had 9 millions in March 2021 in receivables... so when that got paid, the cash went from 3 to 12 millions. Meanwhile, more recent testing increased receivables and they'll get paid later for that and so on. (oversimplified) So based on that, we can presume that in 2-3 months, we'll be around 18-20 millions in cash.. Thats roughly 1/3 of market cap, just in cash...
wildbird1 wrote: In Q1,2021 on $19 million revenues, the increase in cash in the Bank was +$2.6 million(over year end 2020).
Logic would have it that if Q2 tests revenue are less than Q1 tests revenue($19 million), the increase in cash in the Bank would have been less than the Q1 +$2.6 million increase.
On the contrary according to M.Gunter cash in the Bank has increased to $13 million, an increase of +$8.4 million.
An increase of 200% in cash in the Bank over Q1,2021 can't happen if revenues did not increase big time.
We are definitively missing some numbers.
My guess....
The press release do not mention Datametrex New Rapid Antigen tests revenues(only PCR tests are mentioned).
In the Deep Dive video(April 6,2021), M.Gunter said" We have already brought in several purchase orders on these Rapid Antigen Tests.
Trust the numbers...
Cash in the Bank can't increase by 200%($4.6 to $13 million) if revenue did not increase.